| James M Yun, MD | |
|
2423 Nw Troost St, Roseburg, OR 97471-1706 | |
| (541) 677-3400 | |
| (541) 677-3405 |
| Full Name | James M Yun |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 28 Years |
| Location | 2423 Nw Troost St, Roseburg, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144273566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD26302 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Medical Center | Roseburg, OR | Hospital |
| Entity Name | James M Yun Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255667747 PECOS PAC ID: 0244371672 Enrollment ID: O20100107000633 |
News Archive
Rice University bioengineers and physician-scientists at Baylor College of Medicine and Texas Children's Hospital have successfully destroyed tumors of human brain cancer cells in the first animal tests of a minimally invasive treatment that zaps glioma tumors with heat. The tests involved nanoshells, light-activated nanoparticles that are designed to destroy tumors with heat and avoid the unwanted side effects of drug and radiation therapies.
There are about 77,000 people known to have cystic fibrosis. That's from the various cystic fibrosis registries available globally. The World Health Organization suggests that this number may be low, because there's no reporting on cystic fibrosis from the developing world. The accepted number, at the moment, is about 80,000. That's the one that is used for most of the work that's being done on cystic fibrosis.
Janssen R&D Ireland announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis against HIV infection.
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
Researchers say they have evidence to explain what separates your average blood vessel plaque from those that are at high risk for triggering the development of dangerous - even fatal - blood clots.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James M Yun, MD 2423 Nw Troost St, Roseburg, OR 97471-1706 Ph: (541) 677-3400 | James M Yun, MD 2423 Nw Troost St, Roseburg, OR 97471-1706 Ph: (541) 677-3400 |
News Archive
Rice University bioengineers and physician-scientists at Baylor College of Medicine and Texas Children's Hospital have successfully destroyed tumors of human brain cancer cells in the first animal tests of a minimally invasive treatment that zaps glioma tumors with heat. The tests involved nanoshells, light-activated nanoparticles that are designed to destroy tumors with heat and avoid the unwanted side effects of drug and radiation therapies.
There are about 77,000 people known to have cystic fibrosis. That's from the various cystic fibrosis registries available globally. The World Health Organization suggests that this number may be low, because there's no reporting on cystic fibrosis from the developing world. The accepted number, at the moment, is about 80,000. That's the one that is used for most of the work that's being done on cystic fibrosis.
Janssen R&D Ireland announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis against HIV infection.
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
Researchers say they have evidence to explain what separates your average blood vessel plaque from those that are at high risk for triggering the development of dangerous - even fatal - blood clots.
› Verified 4 days ago
Tyson Jarad Dahl, PA-C Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2423 Nw Troost St, Roseburg, OR 97471 Phone: 541-677-3400 Fax: 541-677-3405 | |
Dr. James Dennis Scott, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 300 Independence Ln, Roseburg, OR 97471 Phone: 541-673-3259 | |
Carl S Schreiner, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2423 Nw Troost St, Roseburg, OR 97471 Phone: 541-677-3400 Fax: 541-677-3405 | |
David E. Owens, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1813 W Harvard Ave, Suite 201, Roseburg, OR 97471 Phone: 541-440-6390 Fax: 541-440-6392 |